OVATION SCIENCE INC - OVATF STOCK NEWS

Ovation Science Inc. (CSE:OVAT, OTCQB:OVATF) has announced a new partnership with Pivot Protection Resource, a national distributor for its DermSafe non-alcohol hand sanitizer lotion. This move aims to enhance workplace safety amid the ongoing pandemic, particularly with the rising prevalence of the Delta variant. DermSafe, which uses 4% chlorhexidine gluconate, offers superior germ protection without the drying effects of alcohol. It has shown a 99.97% reduction in the human coronavirus in tests and is recognized by the Canadian Dermatology Review Panel.

Ovation Science Inc. (CSE:OVAT, OTC:OVATF) reports a surge in sales of its non-alcohol hand sanitizer, DermSafe, to athletes across Canada. DermSafe, which contains 4% chlorhexidine gluconate, offers long-lasting germ protection without drying hands. It has shown a 99.97% reduction in the human coronavirus strain OC43. The product has received a Seal of Approval from the Canadian Dermatology Review Panel. Management emphasizes the necessity of such products as athletes return to sports.

Ovation Science Inc. (CSE:OVAT)(OTCQB:OVATF) has launched an online campaign to promote its DermSafe® hand sanitizer, which utilizes Invisicare® technology instead of alcohol. This initiative will feature over 100 articles on Canadian Skin Information's websites, attracting more than 25,000 monthly visitors. DermSafe, effective against COVID-19 with a 99.97% reduction in virus, addresses skin conditions such as dryness and eczema. The campaign aims to boost sales amid retail lockdowns in Canada, providing easy access for consumers.

Ovation Science Inc. has provided an update on its ongoing development of topical and transdermal cannabis products utilizing its patented Invisicare® technology. The company has developed over 30 products, including health and wellness and beauty items, with various CBD to THC ratios. They successfully established a strong market presence in Nevada and aim to expand into other U.S. states. The topical cannabis market is projected to reach $4.5 billion by 2025, marking a significant growth opportunity for Ovation and its unique formulation capabilities.

Ovation Science Inc. (CSE:OVAT)(OTCQB:OVATF) has announced progress in its topical and transdermal cannabis products using patented Invisicare technology. The company now has over thirty products developed, focusing on health, wellness, and beauty. Ovation aims to expand distribution beyond Nevada to other approved US states and is seeking partnerships with multi-state operators. The topical cannabis market is projected to grow to $4.5 billion by 2025, representing a 540% increase. The company has a strong reputation among consumers and budtenders in Nevada.

Ovation Science Inc. announced significant growth in its cannabis product sales, reporting a more than 70% increase in January 2021 compared to December 2020, marking the highest sales since February 2020. The company's royalty income also reached its highest level in the past year. Ovation focuses on topical and transdermal cannabis products, aiming to expand beyond Nevada. Their patented Invisicare technology enhances the absorption of CBD and THC. The broader acceptance of cannabis and increased tourism are expected to drive further growth.

Ovation Science Inc. reported a significant increase in sales through its Nevada licensee, with January 2021 sales surpassing December 2020 by over 70%. This marks the highest sales level since February 2020, reflecting a potential turnaround in the topical cannabis market. The company's royalty income has improved, and CEO Terry Howlett anticipates continued growth as the economy reopens. Ovation's patented Invisicare technology enhances cannabinoid delivery in its products, appealing to a broad market. The overall cannabis topicals segment is projected to reach $4.5 billion by 2025.

Ovation Science Inc. (CSE:OVAT)(OTCQB:OVATF) announced its U.S. listing on the OTCQB Market effective February 23, 2021, enhancing visibility to U.S. investors. The listing is part of Ovation's strategy to broaden its investor base amid increasing interest in the cannabis sector. Additionally, the company received DTC eligibility, facilitating electronic trading of its shares in the U.S. Ovation specializes in topical and transdermal cannabis products, supported by over 20 years of R&D and proprietary delivery technology.

Ovation Science Inc. reported $180,994 in Q3 2020 revenue, marking a 129% increase from Q3 2019 and an 80% rise from Q2 2020. Over nine months, revenue reached $613,157, up 216% year-over-year. Revenue growth is attributed to DermSafe, a patented hand sanitizer lotion. The product's unique formulation has led to its effective marketing strategy, including independent effectiveness studies against coronavirus. CEO Terry Howlett highlighted DermSafe as a promising revenue stream, positioning Ovation to capture market share from traditional sanitizers. The hand sanitizer market is projected to grow significantly.